Utilization Of ProSpeed™ Expression System To Empower Single B Cell Based Antibody Discovery Platform

By Derek Chen, Yu Liang, Lindi Wang, Wenwan Fang, Jie Ma

Single B cell platforms have transformed antibody discovery by offering greater diversity and faster timelines, but they face challenges such as limited assay sensitivity, high costs, and delayed functional screening. These limitations often lead to missed opportunities and inefficiencies, particularly when hit rates are low.

To overcome these hurdles, advanced workflows now incorporate linear expression systems that eliminate the need for time-consuming plasmid preparation and gene synthesis. This integration enables rapid recombinant antibody production directly from exported B cells, allowing functional characterization within days rather than weeks. The result is a significant reduction in turnaround time—from 5–6 weeks to just 2–3 weeks—while improving cost-effectiveness and scalability.

Enhanced assay sensitivity minimizes false negatives and supports multiple rounds of screening, even for complex targets. Additionally, this approach can rescue potential hits that might otherwise be lost due to PCR limitations, ensuring broader sequence diversity and higher success rates. Explore how these innovations streamline antibody discovery and accelerate the path to clinical development.